BR112018013530A2 - ?peptídeo isolado, polinucleotídeo e composição farmacêutica? - Google Patents
?peptídeo isolado, polinucleotídeo e composição farmacêutica?Info
- Publication number
- BR112018013530A2 BR112018013530A2 BR112018013530-5A BR112018013530A BR112018013530A2 BR 112018013530 A2 BR112018013530 A2 BR 112018013530A2 BR 112018013530 A BR112018013530 A BR 112018013530A BR 112018013530 A2 BR112018013530 A2 BR 112018013530A2
- Authority
- BR
- Brazil
- Prior art keywords
- quot
- polynucleotide
- pharmaceutical composition
- isolated peptide
- peptide
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 101100125311 Escherichia coli (strain K12) hyi gene Proteins 0.000 abstract 1
- 101150039312 GIP gene Proteins 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000013559 triple agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a um agonista triplo que tem atividades para todos os receptores de glucagon, glp-1 e gip e usos dos mesmos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0191082 | 2015-12-31 | ||
| KR20150191082 | 2015-12-31 | ||
| KR20160163737 | 2016-12-02 | ||
| KR10-2016-0163737 | 2016-12-02 | ||
| PCT/KR2016/015554 WO2017116204A1 (ko) | 2015-12-31 | 2016-12-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018013530A2 true BR112018013530A2 (pt) | 2018-12-04 |
Family
ID=59225193
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018013530-5A BR112018013530A2 (pt) | 2015-12-31 | 2016-12-30 | ?peptídeo isolado, polinucleotídeo e composição farmacêutica? |
| BR112018013525-9A BR112018013525A2 (pt) | 2015-12-31 | 2016-12-30 | conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018013525-9A BR112018013525A2 (pt) | 2015-12-31 | 2016-12-30 | conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US10370426B2 (pt) |
| EP (3) | EP3398961B1 (pt) |
| JP (5) | JP6712322B2 (pt) |
| KR (8) | KR20170080522A (pt) |
| CN (6) | CN115920077A (pt) |
| AU (4) | AU2016382394B2 (pt) |
| BR (2) | BR112018013530A2 (pt) |
| CA (2) | CA3010265A1 (pt) |
| CL (6) | CL2018001776A1 (pt) |
| CO (2) | CO2018006982A2 (pt) |
| CR (2) | CR20180380A (pt) |
| DK (1) | DK3398961T3 (pt) |
| DO (2) | DOP2018000157A (pt) |
| EA (2) | EA038544B1 (pt) |
| EC (2) | ECSP18053053A (pt) |
| ES (1) | ES2925098T3 (pt) |
| HK (2) | HK1255834A1 (pt) |
| HR (1) | HRP20220995T1 (pt) |
| HU (1) | HUE059737T2 (pt) |
| IL (2) | IL260310B2 (pt) |
| MX (2) | MX2018008128A (pt) |
| PE (1) | PE20181494A1 (pt) |
| PH (2) | PH12018501409A1 (pt) |
| PL (1) | PL3398961T3 (pt) |
| PT (1) | PT3398961T (pt) |
| RS (1) | RS63541B1 (pt) |
| SA (2) | SA518391891B1 (pt) |
| SG (2) | SG11201805573RA (pt) |
| TN (2) | TN2018000231A1 (pt) |
| TW (4) | TWI731015B (pt) |
| WO (2) | WO2017116205A1 (pt) |
| ZA (2) | ZA201804998B (pt) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
| WO2016108586A1 (ko) | 2014-12-30 | 2016-07-07 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| PE20240215A1 (es) | 2015-06-30 | 2024-02-16 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
| TN2018000231A1 (en) | 2015-12-31 | 2019-10-04 | Hanmi Pharm Ind Co Ltd | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
| EP3479841A4 (en) | 2016-06-29 | 2020-03-04 | Hanmi Pharm. Co., Ltd. | GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| JP7121024B2 (ja) | 2017-02-07 | 2022-08-17 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法 |
| MX2019008449A (es) | 2017-02-08 | 2019-09-09 | Bristol Myers Squibb Co | Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos. |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN109239346B (zh) * | 2018-10-31 | 2019-10-11 | 中国药科大学 | 一组代谢标志物在代谢综合征早期诊断方面的应用 |
| US20220088148A1 (en) * | 2018-12-21 | 2022-03-24 | Hanmi Pharm, Co., Ltd. | A pharmaceutical composition comprising insulin and trigonal glucagon/glp-1/gip receptor agonist |
| EP3939990A4 (en) * | 2019-02-15 | 2023-05-24 | Hanmi Fine Chemical Co., Ltd. | NEW INTERMEDIATE USED FOR A BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING IT |
| WO2020214013A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 |
| WO2020214012A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 |
| CN111944055B (zh) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| JP7111917B2 (ja) * | 2019-06-28 | 2022-08-02 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用 |
| MX2022002115A (es) | 2019-08-19 | 2022-03-17 | Lilly Co Eli | Metodos para preparar analogos de incretina. |
| US20230000950A1 (en) * | 2019-10-04 | 2023-01-05 | Hanmi Pharm. Co., Ltd. | Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same |
| CN114641303A (zh) | 2019-11-11 | 2022-06-17 | 勃林格殷格翰国际有限公司 | Npy2受体激动剂 |
| AR120714A1 (es) | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| CN111040022B (zh) * | 2019-12-23 | 2021-12-14 | 万新医药科技(苏州)有限公司 | 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂 |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing Ql Biopharmaceutical Co Ltd | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
| EP4104849A4 (en) * | 2020-01-13 | 2024-03-27 | Hanmi Pharmaceutical Co Ltd | THERAPEUTIC USE OF A LONG-ACTING CONJUGATE OF A TRIPLE AGONIST WITH ACTIVITY RELATED TO GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE |
| CN115916238A (zh) * | 2020-04-20 | 2023-04-04 | 韩美药品株式会社 | 包含胰高血糖素/GLP-l/GIP受体三重激动剂或其缀合物的高血脂症预防或治疗组合物及其使用方法 |
| JP2023526552A (ja) * | 2020-05-22 | 2023-06-21 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ三重活性体の持続型結合体の液状製剤 |
| JP2023535382A (ja) | 2020-07-17 | 2023-08-17 | ハンミ ファーマシューティカル カンパニー リミテッド | 三重作用性持続型結合体又は三重作用剤を含む組合せ物の治療学的用途 |
| BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
| US20230302148A1 (en) | 2020-08-14 | 2023-09-28 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
| MX2023001601A (es) | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip. |
| CN116437967A (zh) | 2020-09-25 | 2023-07-14 | 韩美药品株式会社 | 包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物 |
| WO2022065899A1 (ko) | 2020-09-25 | 2022-03-31 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도 |
| WO2022065897A1 (ko) | 2020-09-25 | 2022-03-31 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 |
| CN115925994B (zh) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| WO2022080984A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| US20230381333A1 (en) * | 2020-10-16 | 2023-11-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis |
| JP2023546384A (ja) | 2020-10-16 | 2023-11-02 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の呼吸器感染疾患の後遺症の治療用途 |
| KR20220050822A (ko) * | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN116635055A (zh) * | 2020-10-16 | 2023-08-22 | 韩美药品株式会社 | 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物 |
| JP2023550594A (ja) | 2020-10-30 | 2023-12-04 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬 |
| MX2023006419A (es) * | 2020-12-02 | 2023-08-15 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Compuestos polipéptidos modificados con lactama. |
| EP4269425A1 (en) | 2020-12-24 | 2023-11-01 | Hanmi Pharm. Co., Ltd. | Novel triple activator that activates all of glucagon, glp-1 and gip receptors, and use thereof |
| WO2022164222A2 (ko) * | 2021-01-29 | 2022-08-04 | 한미약품 주식회사 | Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물 |
| KR20240013798A (ko) | 2021-05-26 | 2024-01-30 | 더 유나이티드 바이오-테크놀로지 (헝친) 컴퍼니 리미티드 | 다중 작용제 및 이의 사용 |
| KR20230004135A (ko) | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| WO2023005841A1 (zh) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
| KR20230095665A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 약물 및 이의 용도 |
| WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202404997A (zh) * | 2022-05-27 | 2024-02-01 | 韓商Ｄ＆Ｄ製藥科技股份有限公司 | 肽組合物及其使用方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5476304A (en) | 1977-11-29 | 1979-06-18 | Tokyo Printing Ink Mfg Co Ltd | Ink |
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| HU229108B1 (en) * | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
| EP2275117B1 (en) * | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| MXPA05009940A (es) * | 2003-03-19 | 2005-12-05 | Lilly Co Eli | Compuestos de glp-1 de enlace de glicol polietilenico. |
| TW200522976A (en) * | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
| ES2495741T3 (es) * | 2006-04-20 | 2014-09-17 | Amgen, Inc | Compuestos de GLP-1 |
| US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| CN101578102B (zh) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| CN102015761A (zh) | 2007-06-19 | 2011-04-13 | 大塚化学株式会社 | 附加糖链的glp-1肽 |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| PA8830501A1 (es) * | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| EA020326B9 (ru) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
| MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EA026384B1 (ru) | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| KR20120123443A (ko) * | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| JP5812627B2 (ja) * | 2010-03-10 | 2015-11-17 | 公益財団法人相模中央化学研究所 | 改良Ｆｃ受容体およびその製造方法 |
| JP6054861B2 (ja) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| JP6284471B2 (ja) | 2011-05-18 | 2018-02-28 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチドの調合薬 |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| DK2718318T3 (en) | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these |
| WO2012173422A1 (en) | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| RU2014101697A (ru) * | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
| JP6396211B2 (ja) | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
| BR112014007124A2 (pt) | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| CN107739409A (zh) | 2012-05-18 | 2018-02-27 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| BR112014031671A2 (pt) * | 2012-06-21 | 2018-08-07 | Hoffmann La Roche | análogos de glucagon exibindo atividade de receptor gip |
| TW201402611A (zh) * | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| AR091477A1 (es) * | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EA034499B1 (ru) | 2012-11-06 | 2020-02-13 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| DK2922877T3 (da) | 2012-11-20 | 2019-01-02 | Eumederis Pharmaceuticals Inc | Forbedrede peptidlægemidler |
| KR20150096433A (ko) * | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
| EP2986314A4 (en) * | 2013-03-15 | 2016-04-13 | Univ Indiana Res & Tech Corp | PROTOCOLS AND A PROLONGED ACTION |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| WO2016108586A1 (ko) | 2014-12-30 | 2016-07-07 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| PE20240215A1 (es) | 2015-06-30 | 2024-02-16 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
| TW201718629A (zh) | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| EP3384935A4 (en) | 2015-12-02 | 2019-08-21 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME |
| TN2018000231A1 (en) * | 2015-12-31 | 2019-10-04 | Hanmi Pharm Ind Co Ltd | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
-
2016
- 2016-12-30 TN TNP/2018/000231A patent/TN2018000231A1/en unknown
- 2016-12-30 PL PL16882156.9T patent/PL3398961T3/pl unknown
- 2016-12-30 EP EP16882156.9A patent/EP3398961B1/en active Active
- 2016-12-30 TW TW105144154A patent/TWI731015B/zh active
- 2016-12-30 CN CN202211656375.4A patent/CN115920077A/zh active Pending
- 2016-12-30 CN CN202211234307.9A patent/CN116063453A/zh active Pending
- 2016-12-30 TN TNP/2018/000228A patent/TN2018000228A1/en unknown
- 2016-12-30 EA EA201891360A patent/EA038544B1/ru unknown
- 2016-12-30 CR CR20180380A patent/CR20180380A/es unknown
- 2016-12-30 JP JP2018534662A patent/JP6712322B2/ja active Active
- 2016-12-30 IL IL260310A patent/IL260310B2/en unknown
- 2016-12-30 IL IL260318A patent/IL260318B2/en unknown
- 2016-12-30 BR BR112018013530-5A patent/BR112018013530A2/pt active Search and Examination
- 2016-12-30 SG SG11201805573RA patent/SG11201805573RA/en unknown
- 2016-12-30 HU HUE16882156A patent/HUE059737T2/hu unknown
- 2016-12-30 TW TW112108994A patent/TW202330585A/zh unknown
- 2016-12-30 CN CN201680082339.8A patent/CN109071624B/zh active Active
- 2016-12-30 AU AU2016382394A patent/AU2016382394B2/en active Active
- 2016-12-30 JP JP2018534682A patent/JP6712323B2/ja active Active
- 2016-12-30 CN CN202211287482.4A patent/CN116059389A/zh active Pending
- 2016-12-30 AU AU2016382393A patent/AU2016382393B2/en active Active
- 2016-12-30 TW TW111101118A patent/TWI807580B/zh active
- 2016-12-30 MX MX2018008128A patent/MX2018008128A/es unknown
- 2016-12-30 HR HRP20220995TT patent/HRP20220995T1/hr unknown
- 2016-12-30 PT PT168821569T patent/PT3398961T/pt unknown
- 2016-12-30 WO PCT/KR2016/015555 patent/WO2017116205A1/ko active Application Filing
- 2016-12-30 BR BR112018013525-9A patent/BR112018013525A2/pt active Search and Examination
- 2016-12-30 EA EA201891359A patent/EA038524B1/ru unknown
- 2016-12-30 MX MX2018008027A patent/MX2018008027A/es unknown
- 2016-12-30 CR CR20180381A patent/CR20180381A/es unknown
- 2016-12-30 WO PCT/KR2016/015554 patent/WO2017116204A1/ko active Application Filing
- 2016-12-30 DK DK16882156.9T patent/DK3398961T3/da active
- 2016-12-30 PE PE2018001233A patent/PE20181494A1/es unknown
- 2016-12-30 RS RS20220774A patent/RS63541B1/sr unknown
- 2016-12-30 CN CN202211234594.3A patent/CN116063454A/zh active Pending
- 2016-12-30 CA CA3010265A patent/CA3010265A1/en active Pending
- 2016-12-30 TW TW105144155A patent/TWI800478B/zh active
- 2016-12-30 CN CN201680082352.3A patent/CN108699125B/zh active Active
- 2016-12-30 KR KR1020160183500A patent/KR20170080522A/ko active Search and Examination
- 2016-12-30 EP EP21201279.3A patent/EP3985017A1/en active Pending
- 2016-12-30 ES ES16882156T patent/ES2925098T3/es active Active
- 2016-12-30 CA CA3010182A patent/CA3010182A1/en active Pending
- 2016-12-30 KR KR1020160183499A patent/KR20170080521A/ko active Search and Examination
- 2016-12-30 EP EP16882157.7A patent/EP3398962A4/en active Pending
- 2016-12-30 SG SG11201805586SA patent/SG11201805586SA/en unknown
-
2018
- 2018-06-25 SA SA518391891A patent/SA518391891B1/ar unknown
- 2018-06-26 SA SA518391903A patent/SA518391903B1/ar unknown
- 2018-06-28 CL CL2018001776A patent/CL2018001776A1/es unknown
- 2018-06-28 DO DO2018000157A patent/DOP2018000157A/es unknown
- 2018-06-29 US US16/023,994 patent/US10370426B2/en active Active
- 2018-06-29 PH PH12018501409A patent/PH12018501409A1/en unknown
- 2018-06-29 CL CL2018001795A patent/CL2018001795A1/es unknown
- 2018-06-29 US US16/024,014 patent/US10400020B2/en active Active
- 2018-06-29 PH PH12018501411A patent/PH12018501411A1/en unknown
- 2018-06-29 DO DO2018000159A patent/DOP2018000159A/es unknown
- 2018-07-04 CO CONC2018/0006982A patent/CO2018006982A2/es unknown
- 2018-07-04 CO CONC2018/0006986A patent/CO2018006986A2/es unknown
- 2018-07-13 EC ECSENADI201853053A patent/ECSP18053053A/es unknown
- 2018-07-13 EC ECSENADI201853055A patent/ECSP18053055A/es unknown
- 2018-07-25 ZA ZA2018/04998A patent/ZA201804998B/en unknown
- 2018-07-25 ZA ZA2018/04997A patent/ZA201804997B/en unknown
- 2018-11-21 HK HK18114910.8A patent/HK1255834A1/zh unknown
-
2019
- 2019-01-14 HK HK19100534.2A patent/HK1258177A1/zh unknown
- 2019-01-31 US US16/263,469 patent/US10981967B2/en active Active
- 2019-03-29 US US16/370,057 patent/US11332508B2/en active Active
- 2019-05-27 KR KR1020190061852A patent/KR102367997B1/ko active IP Right Grant
- 2019-05-27 KR KR1020190061853A patent/KR102401869B1/ko active IP Right Grant
- 2019-06-04 AU AU2019203888A patent/AU2019203888B2/en active Active
- 2019-06-04 AU AU2019203891A patent/AU2019203891B2/en active Active
- 2019-08-29 KR KR1020190106690A patent/KR102179391B1/ko active IP Right Grant
- 2019-08-29 KR KR1020190106691A patent/KR102179392B1/ko active IP Right Grant
-
2020
- 2020-05-29 JP JP2020093904A patent/JP7030894B2/ja active Active
- 2020-05-29 JP JP2020093915A patent/JP2020128428A/ja active Pending
- 2020-07-27 KR KR1020200093189A patent/KR102285377B1/ko active IP Right Grant
- 2020-07-27 KR KR1020200093190A patent/KR102285378B1/ko active IP Right Grant
- 2020-08-05 CL CL2020002033A patent/CL2020002033A1/es unknown
- 2020-08-05 CL CL2020002034A patent/CL2020002034A1/es unknown
-
2021
- 2021-02-26 US US17/187,098 patent/US20210188937A1/en not_active Abandoned
-
2022
- 2022-03-07 CL CL2022000557A patent/CL2022000557A1/es unknown
- 2022-03-07 CL CL2022000558A patent/CL2022000558A1/es unknown
- 2022-03-21 US US17/700,055 patent/US20220213164A1/en active Pending
- 2022-07-07 JP JP2022109549A patent/JP2022130723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018013530A2 (pt) | ?peptídeo isolado, polinucleotídeo e composição farmacêutica? | |
| CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
| PH12017502255A1 (en) | Nrf2 regulators | |
| CL2018001181A1 (es) | Inhibidores de ret | |
| CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
| SV2018005643A (es) | Composiciones de insulina de rapida accion | |
| CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
| UY36292A (es) | Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios | |
| EP3285758A4 (en) | Co-crystal composition and its pharmaceutical use | |
| CL2015001936A1 (es) | Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif). | |
| BR112016027133A8 (pt) | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso | |
| BR112017008867A2 (pt) | inibidores de proteína quinases | |
| EA201791716A1 (ru) | Фармацевтический состав | |
| EP3190129A4 (en) | Centrally-acting peptide derivative, and pharmaceutical composition | |
| AR100289A1 (es) | Formas de un inhibidor de pi3k | |
| DK3424500T3 (da) | Farmaceutisk sammensætning, der omfatter famitinib | |
| EP3295934A4 (en) | Antiviral pharmaceutical composition for topical use | |
| EP3272360A4 (en) | Pharmaceutical composition comprising polypeptide | |
| EP3720417C0 (en) | TOPICAL EMULSION COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |